Aim: Phenobarbital overdose can cause coma and even death. The consciousness disturbance is often prolonged due to its long half-life. In this study, we investigated the efficacy of direct hemoperfusion (DHP) for the removal of phenobarbital by measuring the blood levels of phenobarbital.
Methods: Study subjects included five patients with phenobarbital poisoning who were transferred to our hospital. Direct hemoperfusion was carried out in three of the five patients (six times in total), and the elimination rate was calculated by measuring the blood levels before and after DHP. Furthermore, the disappearance rate of phenobarbital without DHP was calculated in all five patients (seven times in total) for comparison with the elimination rate.
Results: The elimination rate of phenobarbital with DHP was significantly higher than the disappearance rate without DHP．.
Conclusion: This study suggests that early introduction of DHP should be considered as a treatment option for phenobarbital poisoning.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671091 | PMC |
| http://dx.doi.org/10.1002/ams2.601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Granulocyte and Monocyte Adsorption Therapy in Patients With Sepsis: A Feasibility Study.
Artif Organs
January 2025
Laboratory for Immune Response and Regulatory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Background: The pathogenesis of sepsis is thought to be linked to a dysregulated immune response, particularly that involving neutrophils. We have developed a granulocyte adsorption column as a "decoy organ," which relocates the massive inflammation in organs in the body to a blood purification column. This study was conducted to assess the safety and experimental effectiveness of granulocyte monocyte adsorption apheresis-direct hemoperfusion (G1-DHP) in the treatment of patients with sepsis, using a prospective, multicenter design.
View Article and Find Full Text PDFCost-effectiveness of plasmapheresis and hemoperfusion in COVID-19 survivors: A six-month follow-up analysis after hospital discharge.
Ther Apher Dial
January 2025
Department of Health Care Management, Faculty of Health, Tehran Medical Science Branch, Islamic Azad University, Tehran, Iran.
Introduction: To evaluate the short- and long-term clinical and financial outcomes of apheresis in COVID-19 survivors after hospital discharge.
Methods: Intensive care unit-discharged patients were followed for 6 months. Vital signs, laboratory markers, quality of life, and direct medical costs were analyzed to calculate incremental cost-effectiveness ratios (ICER) and to plot cost-effectiveness planes and acceptability curves.
Analysis of Trends and Influencing Factors of Cytokine-Adsorbing Therapies: A Nationwide Ecological Study in Japan.
Cureus
November 2024
Department of Emergency and Critical Care Medicine, Tokyo Metropolitan Tama Medical Center, Tokyo, JPN.
Background: Cytokine-adsorption therapy has garnered attention as a potential treatment for conditions such as sepsis, although supporting evidence remains limited. Consequently, its utilization is expected to vary significantly across regions. To date, no ecological studies have investigated this regional heterogeneity.
View Article and Find Full Text PDFDirect hemoperfusion with polymyxin B immobilized fiber column (PMX) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A prospective multicenter cohort study.
Respir Investig
January 2025
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomioka-Higashi, Kanazawa-ku, Yokohama, Kanagawa, 236-0051, Japan.
Article Synopsis
- - A study investigated the effects of polymyxin B-immobilized fiber column (PMX) treatment on patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), who typically have a poor prognosis.
- - Results showed a survival rate of 65% at day 28 after PMX treatment, which is significantly higher than the usual 40% survival rate seen with conventional treatments.
- - The study concluded that PMX treatment is safe and potentially improves oxygenation and overall prognosis for AE-IPF patients.
Article Synopsis
- The study examined 33 severe COVID-19 patients who underwent a novel hemoperfusion therapy using the Seraph100 filter, aiming to reduce viral RNA levels and markers of inflammation.
- Results showed that while the initial levels of SARS-CoV-2 RNA were generally low and did not significantly change post-treatment, five inflammatory protein analytes exhibited notable decreases, indicating some therapeutic effect on inflammation and endothelial damage.
- The conclusion highlighted that Seraph 100 did not effectively lower viral RNA levels, but it did successfully reduce several inflammatory markers in the blood of these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!